The PAPR Study

Proteomic Assessment of Preterm Risk (PAPR) is a study conducted for the discovery, verification, and validation of preterm birth risk biomarkers. The PAPR study was recruited from 2011-2014. Validation and verification of target proteins was completed in 2015.

1) The PAPR study is the largest study of its kind and is representative of the entire U.S. pregnant population. Blood samples were collected prospectively from 5,501 pregnant women between 17-28 weeks gestation in this large, contemporary, multisite, all-comer study. Eleven highly respected clinical sites from across the U.S. participated.

2) Advanced proteomic technology, bioinformatics, and multidimensional data analysis are being applied to PAPR samples to validate a proprietary biomarker signature designed to reliably predict a woman’s individual risk of delivering preterm. The PAPR study was published as an Editor’s Choice article in the May 2016 American Journal of Obstetrics and Gynecology and can be found here.

The Proteomic Assessment of Preterm Birth study is detailed at the NIH’s clinical trials database site at

“Through a systematic & rigorous approach to biomarker discovery we have cataloged the proteome of pregnancy. These significant discoveries pave the way toward a paradigm shift in obstetrical care in pregnancy and opens the door to the identification of women at risk for aberrant conditions of pregnancy, such as preterm birth”.

Jay Boniface, PhD, Chief Scientific Officer